You are here

Two Next-Generation Correctors Selected to Advance into Phase 3 Triple Combination Development

Two Next-Generation Correctors, VX-659 and VX-445, Selected to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis

January 31, 2018

Vertex announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). This decision was based on positive initial Phase 2 data. Regulatory discussions are ongoing to finalize the design of Phase 3 programs. Upon completion of these discussions, Vertex plans to initiate the first Phase 3 triple combination program in the first half of 2018 to evaluate VX-659 in triple combination, and a second Phase 3 program in mid-2018 to evaluate VX-445 in triple combination.

The Science of Possibility

Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

Join Us

Giving Back

KALYDECO, the KALYDECO logo, ORKAMBI, the ORKAMBI logo, Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.
SYMDEKO and the SYMDEKO logo are trademarks of Vertex Pharmaceuticals Incorporated.
All other trademarks referenced herein are the properties of their respective owners.

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie notice for more information on the use of cookies on this website.